- Home
- TLPH vs PPBT Comparison
TLPH vs PPBT Comparison
Compare TLPH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | PPBT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 45.3M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TLPH | PPBT |
|---|---|---|
| Price | $0.80 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 218.9K | 54.2K |
| Earning Date | 04-06-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.41 |
| 52 Week High | $1.57 | $5.18 |
Technical Indicators
Market Signals| Indicator | TLPH | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 65.89 |
| Support Level | $0.76 | $0.57 |
| Resistance Level | $1.03 | $5.18 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 34.12 | 10.78 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.